You can buy or sell Athenex and other stocks, options, ETFs, and crypto commission-free!
Athenex, Inc. Common Stock, also called Athenex, is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer.It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. Read More The Oncology Innovation Platform segment involves in discovery and development of cancer supportive therapies. The Global Supply Chain Platform segment consists of manufacturing and marketing of API, medical devices, and clinical products. The Commercial Platform segment engages in manufacturing and selling of commercial pharmaceutical products. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.
Buffalo, New York
52 Week High
52 Week Low
Advertising and Marketing
Seeking AlphaMay 11
Athenex, Inc. CEO Johnson Lau on Q1 2019 Results - Earnings Call Transcript
Athenex, Inc. (NASDAQ:ATNX) Q1 2019 Earnings Conference Call May 9, 2019 8:00 AM ET Company Participants Tim McCarthy - Managing Director of LifeSci Advisors Johnson Lau - Chairman & CEO Randoll Sze - CFO Jeffrey Yordon - COO & President of Athenex Pharmaceutical Division Rudolf Kwan - Executive VP & Chief Medical Officer Conference Call Participants Kennen MacKay - RBC Capital Markets Chad Messer - Needham & Company Yale Jen - Laidlaw & Company Raymond Wu - Ladenburg Thalmann Peter Lawson - Sun...
Yahoo FinanceMay 9
Athenex: 1Q Earnings Snapshot
BUFFALO, N.Y. (AP) _ Athenex Inc. (ATNX) on Thursday reported a loss of $35.2 million in its first quarter. On a per-share basis, the Buffalo, New York-based company said it had a loss of 53 cents. The biopharmaceutical company posted revenue of $25.3 million in the period. Athenex shares have risen slightly more than 2% since the beginning of the year. The stock has declined 20% in the last 12 months. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data fro...
Athenex, Inc. Announces First Quarter 2019 Financial Results and Provides Corporate Update
Positive Phase 3 data for KX2-391 featured at 2019 AAD Annual Meeting Promising early and complete response data reported for Oraxol in cutaneous angiosarcoma Topline results from Oraxol Phase III clinical trial expected August 2019 Presenting four abstracts featuring Athenex product candidates at 2019 ASCO annual meeting Approximately 100% year-over-year increase in Q1 product sales Conference Call and Live Audio Webcast at 8:00 a.m. Eastern Time today BUFFALO, N.Y., May 09, 2019 (GLOBE NEWSWIR...
Expected Aug 13, Pre-Market